hVIVO (LON:HVO) Stock Price Up 23% - Here's Why

hVIVO plc (LON:HVO - Get Free Report)'s share price shot up 23% on Tuesday . The stock traded as high as GBX 11 ($0.15) and last traded at GBX 10.70 ($0.15). 24,253,932 shares were traded during mid-day trading, an increase of 569% from the average session volume of 3,624,890 shares. The stock had previously closed at GBX 8.70 ($0.12).

Analyst Ratings Changes

Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a research note on Friday, May 30th.

hVIVO Trading Up 3.4%

The company has a fifty day moving average of GBX 15.92 and a 200-day moving average of GBX 17.70. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The firm has a market capitalization of £76.07 million, a PE ratio of 4.43 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. On average, sell-side analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.